Similar analysis of other types of tumors from TCGA showed that TDRD9 is expressed at high levels in a variable proportion of tumors, ranging from 1% in the case of colon cancer to 50% in acute myeloid tumors (AML) (Supplementary Figure 1). Here, TDRD9 is linked to malignant colon neoplasm.